NASHUA, N.H., Nov. 25, 2014 /PRNewswire/ -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, will feature advanced computer-aided detection (CAD) solutions for the early detection of breast and colon cancers during the 100th Annual Meeting of the Radiological Society of North America (RSNA), in Chicago, Nov. 30 - Dec. 5. Symposia, posters, and workshops discuss the application of iCAD technologies and workflow solutions for enhanced cancer identification, breast density analysis, and tumor characterization. iCAD's 2D mammography, tomosynthesis, and Computed Tomography Colonography (CTC) CAD and workflow technologies will be featured at booth #4135 in Hall A.
"We are pleased to showcase our latest Cancer Detection technologies at the 100th RSNA meeting. Cancer Detection technologies have been proven to help radiologists identify cancer earlier, when there may be more treatment options available," said Ken Ferry, President and CEO of iCAD. "With medical imaging's rapid evolution, iCAD continues to build its CAD offerings to ensure that radiologists have access to the most innovative solutions for optimal patient care."
iCAD will showcase the PowerLook Advanced Mammography Platform (AMP)® and VeraLook® CTC, the first FDA-cleared CAD technology for CTC. PowerLook® has grown to include several modules for breast density assessment, dose assessment and advanced analytics since it was introduced in 2012. iCAD will also be demonstrating a new tomosynthesis workflow tool, as a future product to be released.
The role of volumetric density in adjunctive imaging for women with dense breasts is the topic of numerous poster presentations and workshops. In addition, iCAD's Xoft® cervical brachytherapy for gynecological cancer, MRI imaging for the characterization of pediatric brain tumors and a cloud-based, peer-review platform and workflow solution for large oncology networks will be presented.
Sunday, November 30
- GE Healthcare Workshop: Automated Density Assessment and Screening Breast Ultrasound in Clinical Practice
Jean Weigert, M.D., 1:30-2:00 p.m., Booth #4782
Monday, December 1:
- A Forward Approach for Data Aggregation and Collection to Improve Quality of Peer Review Using a Cloud Based Platform within a Large Oncology Network (Poster)
Dawn Henrich, R.T., director of clinical applications of iCAD, 12:45-1:15 p.m. at ROS-MOB, RO Community, Learning Center
Tuesday, December 2
- Feasibility of Cervical Brachytherapy with a Novel 50 kV Electronic Brachytherapy Source
J. Spencer Thompson, M.D., 11:40-11:50 a.m. in Room S103CD
- System-Wide Monitoring of Mammographic Radiation Dose for Quality Assurance (Poster)
Ralph P Highnam Ph.D., CEO, Matakina Technology Limited CEO, Volpara Solutions Limited 12:45-1:15 p.m. at BR Community, Learning Center
- Fully Automated Volumetric Breast Density Estimation from Digital Breast Tomosynthesis Images: Multi-modality Comparison with Digital Mammography and Breast MRI (Poster)
Said Pertuz Ph.D., 3:20-3:30 p.m. in the Arie Crown Theater
Wednesday, December 3
- ISP: Gastrointestinal (CT Colonography), 10:30 - 12:00 p.m., SSK08, E351
Moderated by Andrea Laghi, M.D. and Judy Yee M.D.
- Present and Future of CT Colonography, SSK08-01
Gastrointestinal Keynote Speaker: Abraham H. Dachman, M.D.
- Present and Future of CT Colonography, SSK08-01
Thursday, December 4
- Breast Imaging (Breast Density and Risk Assessment)
10:30 a.m.-12:00 p.m., Room E450A
Friday, December 5
- Automated processing of dynamic contrast enhanced (DCE) T1 permeability perfusion: advanced pharmacokinetic metrics in pediatric brain tumors
Sridhar Vajapeyam, Ph.D., 11:10 - 11:20 a.m. in Room N229
#MySight: Why we never stop looking
As part of its commitment to the early detection of cancer, iCAD will conduct a social media campaign aimed at supporting the Imerman Angels, a Chicago-based organization that provides one-on-one support to cancer fighters, survivors and caregivers. RSNA attendees can participate by sharing what drives them to "never stop looking" using the hashtag #MySight in social media posts:
- Visit iCAD at RSNA in Hall A, booth #4135 and take a picture at iCAD's #MySight booth station.
- Share the picture on Twitter or Facebook, tag @icadmed and include the hashtag #MySight, and tell us why you "never stop looking."
- For each Tweet or Facebook post that includes #MySight, iCAD will make a donation on your behalf.
Tweets, retweets, mentions, replies, and Facebook posts and shares using the #MySight hashtag during RSNA 2014 (11/30/14 – 12/4/14) are eligible for donation. Posts including the #MySight hashtag from members of the public do not necessarily reflect the views of iCAD and iCAD reserves the right to remove inappropriate, offensive or other material in question at our sole discretion, with or without notice. The #MySight hashtag will not be used for conversations about specific products or treatments. If you have a question about iCAD products, please contact us.
For additional information regarding iCAD and the technologies being discussed at RSNA 2014, please visit http://www.icadmed.com/rsna.html.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while enhancing patient care. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit www.icadmed.com or www.xoftinc.com.
For iCAD investor relations, contact Anne Marie Fields of LHA at 212-838-3777 x6604 or via email at [email protected].
For iCAD media inquiries, contact Lynn Granito of Berry & Company Public Relations, LLC at 212-253-8881 or via email at [email protected].
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company's ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "will", "continue", "anticipate", "likely", "seek", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/icad-showcases-advanced-mammography-and-computed-tomography-colonography-ctc-cad-solutions-at-radiological-society-of-north-america-2014-annual-meeting-300000819.html
SOURCE iCAD, Inc.